In the latest trading session, 1.05 million Evaxion Biotech A/S ADR (NASDAQ:EVAX) shares changed hands as the company’s beta touched -0.26. With the company’s most recent per share price at $2.55 changed hands at -$0.55 or -17.74% at last look, the market valuation stands at $13.31M. EVAX’s current price is a discount, trading about -441.96% off its 52-week high of $13.82. The share price had its 52-week low at $2.82, which suggests the last value was -10.59% down since then. When we look at Evaxion Biotech A/S ADR’s average trading volume, we note the 3-month average coming to 27.73K.
Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information
Instantly EVAX was in red as seen in intraday trades today. With action -23.19%, the performance over the past five days has been red. The drop to weekly highs of 3.48 subtracted -17.74% to the stock’s daily price. The company’s shares are showing year-to-date downside of -62.81%, with the 5-day performance at -23.19% in the red. However, in the 30-day time frame, Evaxion Biotech A/S ADR (NASDAQ:EVAX) is -33.42% down.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Evaxion Biotech A/S ADR (EVAX) estimates and forecasts
Data shows that the Evaxion Biotech A/S ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -62.75% over the past 6 months, a 87.65% in annual growth rate that is considerably higher than the industry average of 15.60%.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 30k. 2 analysts are of the opinion that Evaxion Biotech A/S ADR’s revenue for the current quarter will be 30k.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -18.88%. The 2024 estimates are for Evaxion Biotech A/S ADR earnings to increase by 91.65%.
EVAX Dividends
Evaxion Biotech A/S ADR is expected to release its next quarterly earnings report in July.
